NUCLIDIUM Funding Round Secures €84M for Copper-Based Cancer Radiotheranostics
3 Articles
3 Articles
NUCLIDIUM Funding Round Secures €84M for Copper-Based Cancer Radiotheranostics
NUCLIDIUM, a clinical-stage biotech company based in Basel, has announced the successful close of its €84 million Series B funding round. This financing aims to propel its innovative copper-based radiotheranostic platform designed to revolutionize cancer diagnostics and treatment. The investment was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR, with participation from notable backers such as DeepTe…
Nuclidium fuels next radiopharma wave - European Biotechnology Magazine
Basel-based NUCLIDIUM AG has successfully closed a Series B financing round of CHF 79 million (EUR 84 million) to advance the development of its copper-based radiopharmaceutical platform. The round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR, a company of the Intesa Sanpaolo Group. The post Nuclidium fuels next radiopharma wave appeared first on European Biotechnology Magazine.
Radiopharma’s new wave: Nuclidium and Actithera raise the stakes
Take a closer look at the radiopharma new wave as Nuclidium and Actithera raise big to develop their platforms. The post Radiopharma’s new wave: Nuclidium and Actithera raise the stakes appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided tha…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium